BLASOLUTIONINJECTION
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MERILOG SOLOSTAR (insulin aspart-szjj) by Sanofi is insulin, including insulin aspart products is the regulation of glucose metabolism. Approved for diabetes mellitus, type 2, diabetes mellitus, type 1. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MERILOG SOLOSTAR is a rapid-acting insulin aspart analog approved February 2025 for Type 1 and Type 2 diabetes management. It regulates glucose metabolism by stimulating peripheral glucose uptake in muscle and fat while inhibiting hepatic glucose production. The -SZJJ suffix denotes a biosimilar insulin aspart formulation, representing a newer entrant to the competitive insulin analog market.
Growth
Early-stage growth product with significant competitive headwinds; teams will focus on rapid market penetration and differentiation versus entrenched rapid-acting insulin franchises.
Mechanism of Action
insulin, including insulin aspart products is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis,…
Pharmacologic Class:
Insulin Analog
Indications (2)
Worked on MERILOG SOLOSTAR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.